Gregal

Gregal is a prescription medication that contains the active ingredient tiotropium bromide. It is supplied in an oral dosage form, though the specific strength is not disclosed. Classified as a long‑acting muscarinic antagonist (LAMA) within the bronchodilator therapeutic class, Gregal works by selectively blocking muscarinic M3 receptors in airway smooth muscle. It is marketed in the European Union and is intended for use under medical supervision.

Gregal is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and as an add‑on therapy for asthma when other options are insufficient.

- Long‑term bronchodilation to improve airflow in patients with COPD. - Reduction of COPD exacerbation frequency when used regularly. - Adjunctive control of asthma symptoms in adults with persistent disease. - Support for patients who require once‑daily dosing for convenience. - May be considered in patients who cannot tolerate short‑acting bronchodilators.

The safety profile of Gregal includes both frequently observed and less common adverse events that clinicians monitor during therapy.

Common: - Dry mouth – a sensation of reduced saliva production often reported during the first weeks of therapy. - Cough – transient irritation of the airway that may occur after inhalation or oral administration. - Headache – mild to moderate head pain that can arise without a clear cause.

Serious: - Paradoxical bronchospasm – sudden narrowing of the airways that may worsen breathing difficulty. - Severe allergic reaction (anaphylaxis) – rapid onset of hives, swelling, and respiratory distress requiring emergency care. - Acute urinary retention – difficulty initiating urination that may need medical intervention.

Before prescribing Gregal, healthcare providers should evaluate patient history and consider specific safety considerations to minimize risk.

- Assess for known hypersensitivity to tiotropium bromide or other anticholinergic agents. - Use caution in patients with narrow-angle glaucoma or a history of bladder obstruction. - Monitor renal function, as impaired clearance may increase systemic exposure. - Evaluate cardiovascular status, particularly in individuals with tachyarrhythmias. - Avoid initiating therapy during acute COPD exacerbations without appropriate rescue medication. - Discuss pregnancy and lactation status, noting that safety data are limited.

Gregal may interact with other medications; awareness of potential interactions helps ensure safe co‑administration.

Avoid: - Concomitant use with other anticholinergic drugs (e.g., ipratropium) may increase anticholinergic burden. - Co‑administration with potent CYP3A4 inhibitors, although tiotropium is minimally metabolized, could alter plasma levels.

Use with caution: - Beta‑agonists (short‑acting or long‑acting) may require dose adjustments for optimal bronchodilation. - Diuretics may exacerbate dry mouth; monitor patient comfort. - Theophylline therapy should be monitored for additive respiratory effects.